Pharmacological inhibition of monoacylglycerol lipase enhances IGM plasma levels and limits atherogenesis in a CB2-dependent manner. (August 2018) - Guillamat-prats, R.; Rami, M.; Ring, L.; Rinne, P.; Lenglet, S.; Lauer, E.; Thomas, A.; Cravatt, B.; Weber, C.; Faussner, A.; Steffens, S.